<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title38.html">
                                    Title 38
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/38CFR4.html">Part 4
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  4.117  Schedule of ratings--hemic and lymphatic systems.------------------------------------------------------------------------
                            </h3>
                            <p class="depth0">Rating------------------------------------------------------------------------7700 Anemia, hypochromic-microcytic and megaloblastic, such as</p><p class="depth0">iron-deficiency and pernicious anemia:</p><p class="depth0">Hemoglobin 5gm/100ml or less, with findings such as high         100</p><p class="depth0">output congestive heart failure or dyspnea at rest........</p><p class="depth0">Hemoglobin 7gm/100ml or less, with findings such as dyspnea       70</p><p class="depth0">on mild exertion, cardiomegaly, tachycardia (100 to 120</p><p class="depth0">beats per minute) or syncope (three episodes in the last</p><p class="depth0">six months)...............................................</p><p class="depth0">Hemoglobin 8gm/100ml or less, with findings such as               30</p><p class="depth0">weakness, easy fatigability, headaches, lightheadedness,</p><p class="depth0">or shortness of breath....................................</p><p class="depth0">Hemoglobin 10gm/100ml or less with findings such as               10</p><p class="depth0">weakness, easy fatigability or headaches..................</p><p class="depth0">Hemoglobin 10gm/100ml or less, asymptomatic................        0</p><p class="depth0">Note: Evaluate complications of pernicious anemia, such as dementia or</p><p class="depth0">peripheral neuropathy, separately.</p><p class="depth0">7702 Agranulocytosis, acute:</p><p class="depth0">Requiring bone marrow transplant, or; requiring transfusion      100</p><p class="depth0">of platelets or red cells at least once every six weeks,</p><p class="depth0">or; infections recurring at least once every six weeks....</p><p class="depth0">Requiring transfusion of platelets or red cells at least          60</p><p class="depth0">once every three months, or; infections recurring at least</p><p class="depth0">once every three months...................................</p><p class="depth0">Requiring transfusion of platelets or red cells at least          30</p><p class="depth0">once per year but less than once every three months, or;</p><p class="depth0">infections recurring at least once per year but less than</p><p class="depth0">once every three months...................................</p><p class="depth0">Requiring continuous medication for control................       10</p><p class="depth0">Note: The 100 percent rating for bone marrow transplant shall be</p><p class="depth0">assigned as of the date of hospital admission and shall continue with a</p><p class="depth0">mandatory VA examination six months following hospital discharge. Any</p><p class="depth0">change in evaluation based upon that or any subsequent examination</p><p class="depth0">shall be subject to the provisions of Sec.   3.105(e) of this chapter.</p><p class="depth0">7703 Leukemia:</p><p class="depth0">With active disease or during a treatment phase............      100</p><p class="depth0">Otherwise rate as anemia (code 7700) or aplastic anemia</p><p class="depth0">(code 7716), whichever would result in the greater</p><p class="depth0">benefit.</p><p class="depth0">Note: The 100 percent rating shall continue beyond the cessation of any</p><p class="depth0">surgical, radiation, antineoplastic chemotherapy or other therapeutic</p><p class="depth0">procedures. Six months after discontinuance of such treatment, the</p><p class="depth0">appropriate disability rating shall be determined by mandatory VA</p><p class="depth0">examination. Any change in evaluation based upon that or any subsequent</p><p class="depth0">examination shall be subject to the provisions of Sec.   3.105(e) of</p><p class="depth0">this chapter. If there has been no recurrence, rate on residuals.</p><p class="depth0">7704 Polycythemia vera:</p><p class="depth0">During periods of treatment with myelosuppressants and for       100</p><p class="depth0">three months following cessation of myelosuppressant</p><p class="depth0">therapy...................................................</p><p class="depth0">Requiring phlebotomy.......................................       40</p><p class="depth0">Stable, with or without continuous medication..............       10</p><p class="depth0">Note: Rate complications such as hypertension, gout, stroke or</p><p class="depth0">thrombotic disease separately.</p><p class="depth0">7705 Thrombocytopenia, primary, idiopathic or immune:</p><p class="depth0">Platelet count of less than 20,000, with active bleeding,        100</p><p class="depth0">requiring treatment with medication and transfusions......</p><p class="depth0">Platelet count between 20,000 and 70,000, not requiring           70</p><p class="depth0">treatment, without bleeding...............................</p><p class="depth0">Stable platelet count between 70,000 and 100,000, without         30</p><p class="depth0">bleeding..................................................</p><p class="depth0">Stable platelet count of 100,000 or more, without bleeding.        07706 Splenectomy...............................................       20</p><p class="depth0">Note: Rate complications such as systemic infections with encapsulated</p><p class="depth0">bacteria separately.</p><p class="depth0">7707 Spleen, injury of, healed.</p><p class="depth0">Rate for any residuals.7709 Hodgkin's disease:</p><p class="depth0">With active disease or during a treatment phase............      100</p><p class="depth0">Note: The 100 percent rating shall continue beyond the cessation of any</p><p class="depth0">surgical, radiation, antineoplastic chemotherapy or other therapeutic</p><p class="depth0">procedures. Six months after discontinuance of such treatment, the</p><p class="depth0">appropriate disability rating shall be determined by mandatory VA</p><p class="depth0">examination. Any change in evaluation based upon that or any subsequent</p><p class="depth0">examination shall be subject to the provisions of Sec.   3.105(e) of</p><p class="depth0">this chapter. If there has been no local recurrence or metastasis, rate</p><p class="depth0">on residuals.</p><p class="depth0">7710 Adenitis, tuberculous, active or inactive.</p><p class="depth0">Rate under Sec.  Sec.   4.88c or 4.89 of this part,</p><p class="depth0">whichever is appropriate.7714 Sickle cell anemia:</p><p class="depth0">With repeated painful crises, occurring in skin, joints,         100</p><p class="depth0">bones or any major organs caused by hemolysis and sickling</p><p class="depth0">of red blood cells, with anemia, thrombosis and</p><p class="depth0">infarction, with symptoms precluding even light manual</p><p class="depth0">labor.....................................................</p><p class="depth0">With painful crises several times a year or with symptoms         60</p><p class="depth0">precluding other than light manual labor..................</p><p class="depth0">Following repeated hemolytic sickling crises with                 30</p><p class="depth0">continuing impairment of health...........................</p><p class="depth0">Asymptomatic, established case in remission, but with             10</p><p class="depth0">identifiable organ impairment.............................</p><p class="depth0">Note: Sickle cell trait alone, without a history of directly</p><p class="depth0">attributable pathological findings, is not a ratable disability. Cases</p><p class="depth0">of symptomatic sickle cell trait will be forwarded to the Director,</p><p class="depth0">Compensation Service, for consideration under Sec.   3.321(b)(1) of</p><p class="depth0">this chapter.</p><p class="depth0">7715 Non-Hodgkin's lymphoma:</p><p class="depth0">With active disease or during a treatment phase............      100</p><p class="depth0">Note: The 100 percent rating shall continue beyond the cessation of any</p><p class="depth0">surgical, radiation, antineoplastic chemotherapy or other therapeutic</p><p class="depth0">procedures. Six months after discontinuance of such treatment, the</p><p class="depth0">appropriate disability rating shall be dtermined by mandatory VA</p><p class="depth0">examination. Any change in evaluation based upon that or any subsequent</p><p class="depth0">examination shall be subject to the provisions of Sec.   3.105(e) of</p><p class="depth0">this chapter. If there has been no local recurrence or metastasis, rate</p><p class="depth0">on residuals.</p><p class="depth0">7716 Aplastic anemia:</p><p class="depth0">Requiring bone marrow transplant, or; requiring transfusion      100</p><p class="depth0">of platelets or red cells at least once every six weeks,</p><p class="depth0">or; infections recurring at least once every six weeks....</p><p class="depth0">Requiring transfusion of platelets or red cells at least          60</p><p class="depth0">once every three months, or; infections recurring at least</p><p class="depth0">once every three months...................................</p><p class="depth0">Requiring transfusion of platelets or red cells at least          30</p><p class="depth0">once per year but less than once every three months, or;</p><p class="depth0">infections recurring at least once per year but less than</p><p class="depth0">once every three months...................................</p><p class="depth0">Requiring continuous medication for control................       10</p><p class="depth0">Note: The 100 percent rating for bone marrow transplant shall be</p><p class="depth0">assigned as of the date of hospital admission and shall continue with a</p><p class="depth0">mandatory VA examination six months following hospital discharge. Any</p><p class="depth0">change in evaluation based upon that or any subsequent examination</p><p class="depth0">shall be subject to the provisions of Sec.   3.105(e) of this chapter.7717 AL amyloidosis (primary amyloidosis)                            100------------------------------------------------------------------------

[60 FR 49227, Sept. 22, 1995, as amended at 77 FR 6467, Feb. 8, 2012; 79 FR 2100, Jan. 13, 2014]</p><p class="depth0">The Skin</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
